Neonatal Screening: Cost-utility Analysis for Galactosemia

Overview

Journal Iran J Public Health

Date 2017 Apr 29

PMID 28451536

Citations 4

Authors

Nahid Hatam

Mehrdad Askarian

Samad Shirvani

Elham Siavashi

Affiliations

Soon will be listed here.

Abstract

Background: Galactosemia is a congenital metabolic disorder that can damage the health of a newborn. Screening is an important step to prevent and treat this condition. Due to increasing health care costs and limited financial resources of health systems, the most suitable economic analysis tool should be applied. The aim of this study was to analyze the cost-utility of neonatal screening program for diagnosing galactosemia in Fars province, Iran.

Methods: In this cross-sectional study and cost-utility analysis in the cost of screening for galactosemia and its financial effects, decision tree model and society's viewpoint were used. The population of study was 81837 infants referred to Neonatal Screening Laboratory (Nader Kazemi Clinic) affiliated to Shiraz University of Medical Sciences (SUMS), Iran, in 2010. Quality of life in two groups of patients was evaluated by using the time trade-off. The best intervention option was selected by using the Incremental Cost-effectiveness Ratio.

Results: The estimated cost of diagnosed through screening and without screening were 43519911 and 130011168 Iranian Rails (4222.00 $ and 12615.00 $), respectively. Therefore, there was a saving of 201443240.99 Iranian Rails (19641.00 $), for each patient annually.

Conclusion: The screening program can improve both the qualitative and quantitative lifestyle of people and increase savings in health care system. Policymakers could use the results to design new policies based on the necessity of screening.

Citing Articles

Unusual Presentation of Classical Galactosemia: A Case Report of Iranian Experience.

Alaee M, Saneifard H, Shakiba M, Hanifeh M, Moarefian S Clin Case Rep. 2025; 13(2):e70170.

PMID: 39973892 PMC: 11835960. DOI: 10.1002/ccr3.70170.

The Importance of Neonatal Screening for Galactosemia.

Tisa I, Achim A, Cozma-Petrut A Nutrients. 2023; 15(1).

PMID: 36615667 PMC: 9823668. DOI: 10.3390/nu15010010.

QALY league table of Iran: a practical method for better resource allocation.

Hashempour R, Raei B, Safaei Lari M, Abolhasanbeigi Gallezan N, Akbarisari A Cost Eff Resour Alloc. 2021; 19(1):3.

PMID: 33441153 PMC: 7807517. DOI: 10.1186/s12962-020-00256-2.

Screening for galactosemia: is there a place for it?.

Kotb M, Mansour L, Shamma R Int J Gen Med. 2019; 12:193-205.

PMID: 31213878 PMC: 6537461. DOI: 10.2147/IJGM.S180706.

Galactosaemia - should it be screened in newborns?.

Bosch A Dev Period Med. 2018; 22(3):221-224.

PMID: 30281516 PMC: 8522881.

References

Carroll A, Downs S . Comprehensive cost-utility analysis of newborn screening strategies. Pediatrics. 2006; 117(5 Pt 2):S287-95. DOI: 10.1542/peds.2005-2633H. View

Wang B, Xu Y, Ng W, Wong L . Molecular and biochemical basis of galactosemia. Mol Genet Metab. 1998; 63(4):263-9. DOI: 10.1006/mgme.1998.2678. View

Lund A, Hougaard D, Simonsen H, Andresen B, Christensen M, Duno M . Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland--experience and development of a routine program for expanded newborn screening. Mol Genet Metab. 2012; 107(3):281-93. DOI: 10.1016/j.ymgme.2012.06.006. View

Ko D, Jun S, Park K, Song S, Kim J, Song J . Newborn screening for galactosemia by a second-tier multiplex enzyme assay using UPLC-MS/MS in dried blood spots. J Inherit Metab Dis. 2011; 34(2):409-14. DOI: 10.1007/s10545-011-9291-y. View

Norman R, Haas M, Wilcken B . International perspectives on the cost-effectiveness of tandem mass spectrometry for rare metabolic conditions. Health Policy. 2008; 89(3):252-60. DOI: 10.1016/j.healthpol.2008.08.003. View

Gopalakrishnan V, Joshi K, Phadke S, Dabadghao P, Agarwal M, Das V . Newborn screening for congenital hypothyroidism, galactosemia and biotinidase deficiency in Uttar Pradesh, India. Indian Pediatr. 2014; 51(9):701-5. DOI: 10.1007/s13312-014-0485-x. View

Cuthbert C, Klapper H, Elsas L . Diagnosis of inherited disorders of galactose metabolism. Curr Protoc Hum Genet. 2008; Chapter 17:Unit 17.5. DOI: 10.1002/0471142905.hg1705s56. View

van Erven B, Gubbels C, van Golde R, Dunselman G, Derhaag J, de Wert G . Fertility preservation in female classic galactosemia patients. Orphanet J Rare Dis. 2013; 8:107. PMC: 3718676. DOI: 10.1186/1750-1172-8-107. View

Groselj U, Zerjav Tansek M, Smon A, Angelkova N, Anton D, Baric I . Newborn screening in southeastern Europe. Mol Genet Metab. 2014; 113(1-2):42-5. DOI: 10.1016/j.ymgme.2014.07.020. View

10.

Padilla C, Lam S . Issues on universal screening for galactosemia. Ann Acad Med Singap. 2009; 37(12 Suppl):39-3. View

11.

Ficicioglu C, Thomas N, Yager C, Gallagher P, Hussa C, Mattie A . Duarte (DG) galactosemia: a pilot study of biochemical and neurodevelopmental assessment in children detected by newborn screening. Mol Genet Metab. 2008; 95(4):206-12. DOI: 10.1016/j.ymgme.2008.09.005. View

12.

Ganjekarimi A, Senemar S, Tarami B, Bazrgar M . The prevalence and clinical study of galactosemia disease in a pilot screening program of neonates, southern iran. Iran J Public Health. 2012; 40(4):99-104. PMC: 3481732. View

13.

Jensen U, BRANDT N, Christensen E, Skovby F, Norgaard-Pedersen B, Simonsen H . Neonatal screening for galactosemia by quantitative analysis of hexose monophosphates using tandem mass spectrometry: a retrospective study. Clin Chem. 2001; 47(8):1364-72. View

14.

Elsas 2nd L, Lai K . The molecular biology of galactosemia. Genet Med. 2001; 1(1):40-8. DOI: 10.1097/00125817-199811000-00009. View

15.

Camelo Jr J, Fernandes M, Maciel L, Scrideli C, Ferreira Santos J, Camargo Jr A . Galactosaemia in a Brazilian population: high incidence and cost-benefit analysis. J Inherit Metab Dis. 2009; 32 Suppl 1:S141-9. DOI: 10.1007/s10545-009-1112-1. View

16.

Tiwana S, Rascati K, Park H . Cost-effectiveness of expanded newborn screening in Texas. Value Health. 2012; 15(5):613-21. DOI: 10.1016/j.jval.2012.02.007. View

17.

Agarwal M, Joshi K, Bhatia V, Gopalakrishnan V, Dabadghao P, Das V . Feasibility study of an outreach program of newborn screening in Uttar Pradesh. Indian J Pediatr. 2014; 82(5):427-32. DOI: 10.1007/s12098-014-1557-6. View

18.

Hsieh S, Hsieh S, Chien Y, Weng Y, Hsu K, Chen C . Newborn screening healthcare information system based on service-oriented architecture. J Med Syst. 2010; 34(4):519-30. DOI: 10.1007/s10916-009-9265-x. View

19.

Camelo Junior J, Fernandes M, Jorge S, Maciel L, Santos J, Camargo Jr A . [Newborn screening for galactosemia: a health economics evaluation]. Cad Saude Publica. 2011; 27(4):666-76. DOI: 10.1590/s0102-311x2011000400006. View

20.

Kingsmore S, Lantos J, Dinwiddie D, Miller N, Soden S, Farrow E . Next-generation community genetics for low- and middle-income countries. Genome Med. 2012; 4(3):25. PMC: 3446275. DOI: 10.1186/gm324. View